Early diagnosis of Alzheimer's disease using radiogenomics
Comparison of Subjective Cognitive Decline Between the German and Chinese and Early Diagnosis of Alzheimer's Disease Based on Radiogenomics
This study is trying to find out if certain tests can help spot early signs of Alzheimer's disease in people with memory issues by looking at their brain scans and other health information from participants in Germany and China.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 60 Years to 79 Years |
| Sex | All |
| Sponsor | Xuanwu Hospital, Beijing Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT04696315 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the mechanisms underlying subjective cognitive decline (SCD) as a precursor to Alzheimer's disease (AD) by comparing participants from Germany and China. It will involve amyloid PET scanning to classify SCD patients into those with and without amyloid pathology, followed by an analysis of clinical, genetic, blood, and MRI data. The goal is to identify common and specific features of SCD across different cultures and to establish a diagnostic model for preclinical AD. The study will also track participants over four years to identify risk factors for conversion to cognitive impairment and dementia.
Who should consider this trial
Good fit: Ideal candidates are Mandarin-speaking individuals aged 60-79 who report a persistent decline in cognitive capacity without meeting criteria for mild cognitive impairment or dementia.
Not a fit: Patients with a history of stroke, major depression, or other central nervous system diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved early diagnostic methods for Alzheimer's disease, allowing for timely interventions.
How similar studies have performed: Other studies have shown promise in using radiogenomics for early diagnosis of Alzheimer's, but this specific cross-cultural approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 60-79 years old, right-handed and Mandarin-speaking subjects; * self-experienced persistent decline in cognitive capacity in comparison with a previously normal status and unrelated to an acute event; * normal age-, gender- and education-adjusted performance on standardised cognitive tests; * concerns (worries) associated with memory complaint; * failure to meet the criteria for MCI or dementia Exclusion Criteria: * a history of stroke; * major depression (Hamilton Depression Rating Scale score \> 24 points); * other central nervous system diseases that may cause cognitive impairment, such as Parkinson's disease, tumors, encephalitis and epilepsy; * cognitive impairment caused by traumatic brain injury; * systemic diseases, such as thyroid dysfunction, syphilis and HIV; * a history of psychosis or congenital mental growth retardation
Where this trial is running
Beijing, Beijing
- Department of Neurolgy, Xuanwu Hospital of Capital Medical University — Beijing, Beijing, China (Recruiting)
Study contacts
- Principal investigator: Ying Han, PhD — Xuanwu Hospital of Capital Medical University
- Study coordinator: Ying Han, PhD
- Email: 13621011941@163.com
- Phone: 86-18515692701
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.